Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.

EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced ...

A new technical paper, “Cascade: Composing Software-Hardware Attack Gadgets for Adversarial Threat Amplification in Compound AI Systems,” was published by the University of Texas, Austin, Intel Labs, ...

Biogen has announced a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion, a move that would expand its presence in complement-mediated diseases, including ...

EMPAVELI (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced ...

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, ...

A Pacific storm is set to sweep into the Pacific Northwest midweek, bringing a mix of steady rain, strong coastal winds and ...

A metabolic enzyme found in the support cells surrounding tumors may hold the key to predicting which cancer patients will ...

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence ...

Our communities and critical infrastructure are facing security and safety risks that are constantly evolving, and the protections needed to secure this infrastructure must catch up.

Learn how reforming Nigeria's civil service through enhanced policy intelligence, professionalism, and data-driven strategies can overcome execution failur ...

This article argues for the adoption of a combined lyophilized plasma and platelet product strategy to address critical gaps.